| COVID-19 |
1 |
1 |
| Myocarditis |
0 |
0.7 |
| Cardiomyopathy |
0 |
0.67 |
| Exercise |
0 |
0.45 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.45 |
| Arrhythmia |
0 |
0.38 |
| Cardiovascular Stress Testing |
0 |
0.34 |
| Chest Pain |
0 |
0.24 |
| Cardiovascular Imaging |
0 |
0.23 |
| Acute Respiratory Distress Syndrome |
0 |
0.21 |
| Severe Acute Respiratory Syndrome |
0 |
0.19 |
| Heart Failure (HF) |
0 |
0.18 |
| Pain Management |
0 |
0.17 |
| Angina Pectoris |
0 |
0.16 |
| Cardiac MRI |
0 |
0.16 |
| Thorax |
0 |
0.16 |
| Troponin |
0 |
0.16 |
| Sports Medicine |
0 |
0.15 |
| Cardiovascular Risk Management |
0 |
0.14 |
| Deep Venous Thrombosis |
0 |
0.14 |
| Pulmonary Embolism |
0 |
0.14 |
| Vaccines |
0 |
0.14 |
| Dyspnea |
0 |
0.13 |
| Pain |
0 |
0.13 |
| Palpitations |
0 |
0.13 |
| Pneumonia |
0 |
0.13 |
| Electrophysiology |
0 |
0.12 |
| Cardiovascular disease |
0 |
0.1 |
| Corticosteroids |
0 |
0.1 |
| Echocardiography |
0 |
0.1 |
| Electrocardiogram (ECG) |
0 |
0.1 |
| Heart |
0 |
0.1 |
| Immunization |
0 |
0.1 |
| Tachycardia |
0 |
0.1 |
| Biopsy |
0 |
0.06 |
| Fatigue |
0 |
0.06 |
| Injury |
0 |
0.06 |
| Wound Management |
0 |
0.06 |
| Calcium Channel Blockers |
0 |
0.04 |
| Orthostatic Hypotension |
0 |
0.04 |
| Athletics |
0 |
0.03 |
| Beta Blockers |
0 |
0.03 |
| Calcium |
0 |
0.03 |
| Clinical Guidelines |
0 |
0.03 |
| Fever |
0 |
0.03 |
| Hemodynamics |
0 |
0.03 |
| Hypotension |
0 |
0.03 |
| Intravenous |
0 |
0.03 |
| Muscle |
0 |
0.03 |
| Nonpharmacologic |
0 |
0.03 |
| Nonsteroidal Anti-Inflammatory Agents |
0 |
0.03 |
| Orthostatic Intolerance |
0 |
0.03 |
| Osteoarthritis |
0 |
0.03 |
| Pulmonary Function Test |
0 |
0.03 |
| Quality of Life |
0 |
0.03 |
| Syncope |
0 |
0.03 |
| Washington |
0 |
0.03 |